The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma

  • Kang, Myung-Hee (Department of Internal Medicine, Gyeongsang National University School of Medicine) ;
  • Ju, Ji-Hyun (Department of Internal Medicine, Gyeongsang National University School of Medicine) ;
  • Kim, Hoon-Gu (Department of Internal Medicine, Gyeongsang National University School of Medicine) ;
  • Kang, Jung-Hun (Department of Internal Medicine, Gyeongsang National University School of Medicine) ;
  • Jeon, Kyung-Nyeo (Institute of Health Science, Gyeongsang National University School of Medicine) ;
  • Kim, Ho-Cheol (Department of Internal Medicine, Gyeongsang National University School of Medicine) ;
  • Lee, Gyeong-Won (Department of Internal Medicine, Gyeongsang National University School of Medicine)
  • Received : 2007.12.28
  • Accepted : 2008.03.28
  • Published : 2010.12.01
⟨ Previous Next ⟩

Abstract

A 63-year-old female diagnosed with relapsed multiple myeloma visited our hospital complaining of a persistent cough. Since July 2006, she had been taking 100 mg thalidomide daily and gradually developed shortness of breath and a persistent dry cough. A chest X-ray and computed tomography showed ground glass opacities in both lungs. An open lung biopsy of the right middle lobe under general anesthesia revealed chronic peribronchial inflammation, mild interstitial fibrosis, and intra-alveolar macrophage infiltration, with some hemosiderin features, compatible with non-specific interstitial pneumonia (NSIP). After discontinuing the thalidomide, the patient's symptoms did not deteriorate, although the radiographs did not improve. The patient is alive and well with regular outpatient follow-up without progression of the NSIP.

Keywords

References

  1. Raje N, Anderson K. Thalidomide: a revival story. N Engl J Med 1999;341:1606-1609. https://doi.org/10.1056/NEJM199911183412110
  2. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-1893.
  3. Epler GR. Drug-induced bronchiolitis obliterans organizing pneumonia. Clin Chest Med 2004;25:89-94. https://doi.org/10.1016/S0272-5231(03)00140-0
  4. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004;91 Suppl 2:S18-S23.
  5. Feaver AA, McCune DE, Mysliwiec AG, Mysliwiec V. Thalidomide-induced organizing pneumonia. South Med J 2006;99:1292-1294. https://doi.org/10.1097/01.smj.0000233182.06540.00
  6. Iguchi T, Sakoda M, Chen CK, et al. Interstitial pneumonia during treatment with thalidomide in a patient with multiple myeloma. Rinsho Ketsueki 2004;45:1064-1066.
  7. Carrion Valero F, Bertomeu Gonzalez V. Lung toxicity due to thalidomide. Arch Bronconeumol 2002;38:492-494. https://doi.org/10.1016/S0300-2896(02)75272-1
  8. Behrens RJ, Gulley JL, Dahut WL. Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther 2003;10:228-232. https://doi.org/10.1097/00045391-200305000-00011
  9. Onozawa M, Hashino S, Sogabe S, et al. Side effects and good effects from new chemotherapeutic agents. Case 2: thalidomideinduced interstitial pneumonitis. J Clin Oncol 2005;23:2425-2426. https://doi.org/10.1200/JCO.2005.04.054

Cited by

  1. Antineoplastic therapy-induced pulmonary toxicity vol.13, pp.8, 2013, https://doi.org/10.1586/14737140.2013.817684
  2. Thalidomide-induced bronchiolitis obliterans organizing pneumonia in a patient with multiple myeloma vol.30, pp.4, 2010, https://doi.org/10.4103/1319-2442.265477